Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity

Motley Fool11-13 16:15

Vertex Pharmaceuticals has become a leader in cystic fibrosis treatment, bringing in blockbuster revenue every year. Now, this biotech is ready to tackle a very common health problem -- and it’...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483039078?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797520%2Fgettyimages-1253877215.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-11-13 16:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483039078","market":"fut","top_or_hot":-1,"title":"Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity","media":"Motley Fool","content":"<div>\n<p>Vertex Pharmaceuticals has become a leader in cystic fibrosis treatment, bringing in blockbuster revenue every year.\n\n\n\n\n\n\n\nNow, this biotech is ready to tackle a very common health problem -- and it’...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/13/prediction-this-biotech-stock-is-heading-for-a-onc/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/11/13/prediction-this-biotech-stock-is-heading-for-a-onc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals has become a leader in cystic fibrosis treatment, bringing in blockbuster revenue every year.\n\n\n\n\n\n\n\nNow, this biotech is ready to tackle a very common health problem -- and it’...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/13/prediction-this-biotech-stock-is-heading-for-a-onc/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1430594728.SGD","symbol_name":"Eastspring Investments - Global Low Volatility Equity AS SGD","start_time":0,"source_url":"https://www.fool.com/investing/2024/11/13/prediction-this-biotech-stock-is-heading-for-a-onc/","article_id":"2483039078","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797520%2Fgettyimages-1253877215.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483039078","pubTimestamp":1731485700,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Regulators are reviewing what could become a multi-billion-dollar drug.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4139":"生物科技","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","VRTX":"福泰制药","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","VERX":"Vertex, Inc.","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4093":"化肥与农用药剂","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4023":"应用软件","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","CF":"CF工业","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD"},"translate_title":"预测：这只生物科技股正迎来千载难逢的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CF":1,"VRTX":0.9,"VERX":0.9},"content_text":"Vertex Pharmaceuticals has become a leader in cystic fibrosis treatment, bringing in blockbuster revenue every year.\n\n\n\n\n\n\n\nNow, this biotech is ready to tackle a very common health problem -- and it’s also an area of great need.\n\nBiotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals (VRTX -2.34%) has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company's portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue -- in the most recent quarter, product revenue climbed in the double digits to nearly $2.8 billion.In recent years, investors appreciated Vertex's dominance in the CF market, but some worried about the company's focus on only one treatment area. These days, though, Vertex is on the path to eliminating those worries. Earlier this year, it launched a treatment for blood disorders, and today it's about to address one of the world's most common health problems -- a market where need is particularly high. My prediction is that Vertex is heading for a once-in-a-generation opportunity, and investors who get in on the stock today should benefit for years to come. Let's find out more.Image source: Getty Images.A \"multibillion-dollar franchise\" for VertexI call this a once-in-a-generation opportunity because it isn't every day that a company launches a drug that may tackle a problem plaguing so many. Serving this market should, as Vertex says, result in a \"multibillion-dollar franchise\" for the company. Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, for the treatment of acute pain. The FDA has pledged to issue a decision by the target date of Jan. 30.In the U.S. alone, more than 80 million people annually ask their doctors for prescriptions to treat moderate to severe acute pain, and the problem is that options are limited. Over-the-counter pills aren't always effective, and opioid prescription drugs come with the risk of addiction. Vertex has developed a non-opioid candidate, therefore eliminating addiction risk. At the same time, the drug has demonstrated strong efficacy in clinical trials. Suzetrigine works by stopping the sodium channel known as NaV1.8 from transmitting pain signals.Vertex has already prepared for a potential FDA nod, with teams hired, trained, and ready for launch. The company's two initial goals are to ensure retail distribution across the U.S. and create a financial assistance program to immediately support patient access. Suzetrigine is an oral treatment and doesn't require patients to take any particular tests before giving it a try. These elements should favor a rapid launch.Legislation is another element that may help suzetrigine. The NOPAIN Act, which goes into effect at the start of the year, offers an add-on payment for the prescription of non-opioids in hospital outpatient and ambulatory surgery settings. More to come...All this sounds great, but this may be just the beginning for suzetrigine and Vertex's pain portfolio. The company has launched a phase 3 program for suzetrigine in diabetic peripheral neuropathic pain. This indication represents a potential patient group of 2 million in the U.S. The company has also completed a phase 2 trial for suzetrigine in a type of back pain called lumbosacral radiculopathy. About 4 million Americans seek prescriptions for this type of peripheral neuropathic pain every year. Meanwhile, Vertex continues to study other pain candidates and says its goal is \"to fundamentally change the way pain is treated.\"The sheer size of the pain market -- and I've just spoken about the U.S. here -- is so vast that addressing it with a safe and effective product could be a game changer for patients, and for Vertex and its investors. It's important to remember that Vertex is already a successful biotech player, bringing in blockbuster revenue thanks to its CF program. And the company has more than $11 billion in cash, meaning it has what it takes to shepherd pain and other candidates through the pipeline or even acquire new programs when the opportunity arises.So, Vertex's complete picture looks bright. On top of this, my prediction that Vertex is heading for a once-in-a-generation opportunity right now could make that picture even brighter. The pain portfolio could drive a new era of growth in earnings and stock performance, making now a great time to buy Vertex shares and hold on for the long term.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483039078"}